Fraud-prevention software developer Adveritas (ASX: AV1) has completed an $8.5 million placement to existing shareholders and new institutional investors ...

Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, ...